Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 5,453 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: SOLID TUMORS Clear all
Completed No phase listed Observational

Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion

NCT02376127
View directory record Official record
Conditions
Solid Cancer, Metastatic Spinal Lesions
Interventions
Dynamic contrast enhancement MRI
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of ASTX029 in Subjects With Advanced Solid Tumors

NCT03520075
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
ASTX029
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Phase 1 Interventional

An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors

NCT01406119
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ABT-806
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 17, 2026, 7:26 AM EDT
Recruiting Phase 2 Interventional

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06760819
View directory record Official record
Conditions
Advanced Solid Tumors, HER2 Mutation
Interventions
BAY2927088
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Birmingham, Alabama • Duarte, California • Fort Myers, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 7:26 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

NCT05222165
View directory record Official record
Conditions
Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma
Interventions
Infigratinib
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 17, 2026, 7:26 AM EDT
Terminated Phase 1 Interventional

A Study of SGN-ALPV in Advanced Solid Tumors

NCT05229900
View directory record Official record
Conditions
Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Gastroesophageal Junction Carcinoma, Uterine Cervical Neoplasms, Testicular Neoplasms
Interventions
SGN-ALPV
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Fresno, California • New Haven, Connecticut • Wellington, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Phase 1 Interventional

SU5416 and Paclitaxel in Treating Patients With Advanced Cancer

NCT00006257
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
paclitaxel, semaxanib
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 17, 2026, 7:26 AM EDT
Withdrawn Early Phase 1 Interventional

Thermal Therapy for the Treatment of Depression in Cancer Survivors, the S-WARM Study

NCT04803630
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Thermotherapy
Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 17, 2026, 7:26 AM EDT
Terminated Phase 1 Interventional

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

NCT05576077
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
TBio-4101, Pembrolizumab
Biological · Drug
Lead sponsor
Turnstone Biologics, Corp.
Industry
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Irvine, California • Hollywood, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors

NCT02900157
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
MEDI9090, Durvalumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Phase 1 Interventional

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

NCT00004212
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim, exatecan mesylate
Biological · Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
4
States / cities
New York, New York • Memphis, Tennessee • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Phase 1 Interventional

URMC Related Haplo-identical Donor BMT

NCT02660281
View directory record Official record
Conditions
Hematological Disease, Immune Deficiencies, Solid Tumors, Myelofibrosis, Multiple Myeloma, Lymphoma
Interventions
Total Body Irradiation 1200 cGy, Fludarabine, Pre-Stem Cell Infusion Cyclophosphamide, Pre-Stem Cell Infusion Mesna, Busulfan, Melphalan, Stem Cell Infusion, Post-Stem Cell Infusion Cyclophosphamide, Post-Stem Cell Infusion Mesna, Thiotepa
Radiation · Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
6 Months to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Not applicable Interventional Results available

Individualized Stereotactic Body Radiotherapy of Liver Metastases

NCT01239381
View directory record Official record
Conditions
Solid Tumor, Liver Metastases
Interventions
Stereotactic body radiotherapy-proton
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 17, 2026, 7:26 AM EDT
Completed No phase listed Observational

Bone Mineral Density in Adult Survivors of Solid Pediatric Cancers

NCT00634816
View directory record Official record
Conditions
Regional Osteoporosis as a Result of Chemotherapy
Interventions
DXA Scan
Radiation
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
16 Years to 40 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 17, 2026, 7:26 AM EDT
Active, not recruiting Not applicable Interventional

The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer

NCT05023993
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Prediabetes
Interventions
Exercise Intervention, Nicotinamide Riboside
Other · Dietary Supplement
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

NCT02499328
View directory record Official record
Conditions
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions
AZD9150, MEDI4736, AZD5069, tremelimumab (treme)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 17, 2026, 7:26 AM EDT
Terminated Phase 1 Interventional

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

NCT04553692
View directory record Official record
Conditions
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
Interventions
Aplitabart (IGM-8444), FOLFIRI, Bevacizumab (and approved biosimilars), Birinapant, Venetoclax, Gemcitabine, Docetaxel, Azacitidine
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
37
States / cities
Phoenix, Arizona • Duarte, California • Los Alamitos, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Phase 1 Interventional

Ro 31-7453 in Treating Patients With Metastatic Solid Tumors

NCT00014365
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
MKC-1
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Phase 1 Interventional

Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors

NCT02239900
View directory record Official record
Conditions
Liver Cancer, Lung Cancer
Interventions
Ipilimumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Phase 1 Interventional

Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors

NCT00253565
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
capecitabine, imatinib mesylate
Drug
Lead sponsor
Herbert Hurwitz
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Oct 17, 2026, 7:26 AM EDT
Terminated Phase 1 Interventional

A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors

NCT00724100
View directory record Official record
Conditions
Cancer
Interventions
ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)
Drug
Lead sponsor
Albany Molecular Research, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2014 · Synced Oct 17, 2026, 7:26 AM EDT
Terminated Phase 1 Interventional

Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors

NCT04301011
View directory record Official record
Conditions
Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cervical Cancer, Melanoma (Skin), Cutaneous Squamous Cell Carcinoma, Mesothelioma, Renal Cell Carcinoma, Oropharynx Cancer
Interventions
TBio-6517, Pembrolizumab
Biological
Lead sponsor
Turnstone Biologics, Corp.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Phase 1 Interventional

A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

NCT03215511
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
Selitrectinib (BAY2731954)
Drug
Lead sponsor
Bayer
Industry
Eligibility
1 Month and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Phase 1 Interventional

Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors

NCT00502892
View directory record Official record
Conditions
Solid Tumors
Interventions
Topotecan, Ifosfamide, Carboplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 45 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 17, 2026, 7:26 AM EDT